Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ROCKET PHARMACEUTICALS, INC. (RCKT)
|
Add to portfolio |
|
|
|
| Price: |
$42.07
| | Metrics |
| OS: |
80.5
|
M
| |
|
|
| Market cap: |
$3.39
|
B
| |
|
|
|
Net cash:
|
$307
|
M
| |
$3.81
|
per share
|
|
EV:
|
$3.08
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | | | | | | | -100.0% |
| Cost of goods sold | 1.2 | 1.1 | 0.9 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | -1.2 | -1.1 | -0.9 | -0.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Research and development | 165.6 | 125.5 | 105.4 | 57.9 | 53.3 | 14.9 | 6.0 | 12.6 |
| General and administrative | 58.8 | 41.8 | 28.9 | 18.2 | 17.9 | 4.9 | 1.6 | 7.8 |
| EBIT | -224.3 | -167.2 | -134.3 | -76.2 | -71.2 | -19.8 | -7.6 | -20.4 |
| EBIT margin | | | | | | | | |
| Pre-tax income | -221.9 | -169.1 | -139.7 | -77.3 | -74.5 | -19.6 | -7.6 | -68.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -221.9 | -169.1 | -139.7 | -77.3 | -74.5 | -19.6 | -7.6 | -68.0 |
| Net margin | | | | | | | | |
| |
| Diluted EPS | ($3.26) | ($2.67) | ($2.52) | ($1.58) | ($1.89) | ($2.88) | ($1.11) | ($3.71) |
| Shares outstanding (diluted) | 68.1 | 63.2 | 55.4 | 49.0 | 39.4 | 6.8 | 6.8 | 18.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|